We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BD Advances Entry into NGS with Acquisition of GenCell Biosystems

By LabMedica International staff writers
Posted on 26 Oct 2014
Leading medical technology company Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) has acquired GenCell Biosystems (Limerick, Ireland), a privately-held biotech company that has developed proprietary technologies that address key biological analysis protocols —from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications.

“We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare,” said Linda Tharby, Group President, BD, “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”

GenCell Biosystems is an Enterprise Ireland-supported company whose headquarters and manufacturing are based in Limerick (Ireland), and operates a USA marketing, sales, and service group in Madison (WI, USA). More...
Founded in 2011, GenCell has created an automated platform that has the potential to address key unmet customer needs in library preparation for NGS.

Kieran Curran, CEO and founder of GenCell, commented, “We are looking forward to joining with BD to provide great solutions for our current and future customers in Next Generation Sequencing. In a short amount of time we have been able to move CLC technology from concept to product. We believe we will now be able to scale up and introduce further transformative innovation in NGS-related segments.”

Financial details on the acquisition are not being disclosed at this time. The expected impact of this transaction will be reflected in guidance that will be communicated on BD’s fourth quarter earnings call.

Related Links:

Becton, Dickinson and Company (BD)
GenCell Biosystems



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.